Podcasts about Novartis

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen?

On this episode of #TheShot of #DigitalHealth Therapy, Jim Joyce and I had the pleasure of chatting with the globally minded and endlessly curious Alette Ramos Hunt, PhD, Global Director, Digital Innovation & AI for Drug Discovery at Novartis. From being a third culture kid (Danish dad, Filipino mom, born in Japan, raised in Hong Kong) to becoming one of the sharpest voices connecting biotech, digital health, and AI, Alette brings perspective that's as international as it is insightful. We explored her fascinating path from studying proteins in Glasgow to driving AI innovation in pharma, and how she's bridging the gap between molecules, humans, and machines. She reminded us that practical AI and game-changing AI both have a place - one makes us efficient, the other makes us dream bigger. It's an episode filled with humility, humor, and yes.. human intelligence - proving that even in a world of algorithms, empathy still leads the way. Fun mentions as always: Chandana Fitzgerald Jeff Weness Milind Kamkolkar [00:00-02:00] Bloopers, sunshine, and background banter. [00:03-05:00] Alette's third-culture upbringing — Japan, Hong Kong, Denmark. [00:05-07:00] Boarding school, biochemistry, and falling in love with proteins. [00:10-12:00] From academia to Pfizer — bringing science to life. [00:13-15:00] Leap to HealthXL — discovering digital health beyond the lab. [00:18-21:00] Entering Novartis — pre-ChatGPT AI strategy and innovation cycles. [00:22-25:00] Practical AI vs. game-changing AI — redefining productivity. [00:24-28:00] AI and drug discovery — startups, partnerships, and collaboration. [00:29-34:00] Lessons on open-minded leadership and partnering with purpose. [00:36-39:00] Jim's classic closing story and Alette's advice: Value your strengths, cherish your partners.

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 31, 2025. In this episode: third quarter dealmaking picks up; Novartis still has M&A firepower even after Avidity acquisition; Hanmi's obesity contender shows Phase III promise; NVIDIA partnership progresses Lilly's AI plans; and Lilly builds gene therapy push with Adverum buy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-MQMX2YHSAVHBTJFR4RAEAYNFNQ/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

This Week in Review covers 5 episodes from October 27 to October 31, featuring major developments in the pharmaceutical and biotech industries.Episodes included:1. Pharma Shifts: Dual-Action Obesity Drugs & Regulatory Waves2. Navigating Pharma's New Frontiers: Breakthroughs and Challenges3. Gene Therapy Challenges and Regulatory Shifts: Industry Innovations4. Biotech Breakthroughs: Transformative Acquisitions and FDA Milestones5. Novartis' $12B RNA Therapeutics BreakthroughKey topics covered:- Strategic acquisitions and partnerships- Regulatory updates and FDA approvals- Clinical trial results and breakthroughs- Industry trends and market developmentsStay informed with Pharma Daily's comprehensive coverage of the pharmaceutical and biotech world.Support the show

Des résultats excellents ? “Pas assez bons.” Des prévisions solides ? “Pas assez ambitieuses.” Et pendant ce temps, on avance les yeux bandés, entre Powell qui baisse les taux sans promettre la suite, Trump qui signe la paix avec Xi sans vraiment y croire, et un shutdown américain qui bat tous les records. Tout le monde veut du parfait, du brillant, du spectaculaire… mais plus personne ne sait vraiment ce qu'il cherche. Le marché veut monter, mais il a la gueule de bois. L'économie veut ralentir, mais elle continue de boire du Red Bull monétaire. Bref : on est dans une partie géante de colin-maillard financier, et les murs se rapprochent doucement. Bienvenue dans Swiss Bliss, édition du 1er novembre 2025. On parle résultats, Fed, Trump, Suisse… et surtout d'un marché qui ne veut plus rien entendre — sauf le son de sa propre euphorie

On this week's episode, Daphne Zohar, Bruce Booth, Sam Fazeli, Brian Skorney, Yaron Werber, and Eric Schmidt kick off with market updates, noting that the XBI is showing signs of a sustainable recovery after years of underperformance and highlighting that the IPO market is likely closed for the remainder of the year, but note optimism for early 2026. In deal news, Novartis' $12B acquisition of Avidity is spotlighted as an unprecedented move for a company yet to read out Phase 3 data. The co-hosts also speculate on what this acquisition could mean for Dyne Therapeutics, has a similar RNA-based pipeline in rare muscle disease. Next, Daphne highlights that some of the biggest M&A deals of the year have come from women-led companies - including Avidity. The conversation then shifts to Novo Nordisk's surprise $9Bbid for Metsera, which challenges Pfizer's existing $7.3B deal and raises questions about Novo's intentions. In policy news, manufacturing issues at Novo's Catalent Indiana facility and the impact on the sector are mentioned. The episode concludes with a group discussion around Bruce's lessons from his 20 years in early-stage biotech. *This episode aired on October 31, 2025.

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über KI-Manie an der Wall Street, eine Gewinnwarnung bei Symrise und die lukrativen Lehren aus 200 Jahren Börsenhistorie. Außerdem geht es um Alphabet, Meta, Microsoft, Deutsche Bank, Boeing, Caterpillar, Apple, Amazon, Paypal, UPS, SK Hynix, Wayfair, Draftkings, Flutter, Trump Media & Technology, Booking Holdings, Bloom Energy, BNP Paribas, Novartis, Huawei, ZTE, Siemens, iShares Core MSCI World (WKN: A0RPWH), Amundi MSCI All Country World (WKN: LYX00C), Xtrackers MSCI World ex USA (WKN: DBX0VH), iShares Core S&P 500 (WKN: A0YEDG). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Vanderlei e a esposa tinham planejado alguns dias de descanso em Fortaleza, mas, no meio de um passeio na praia, ele começou a se sentir muito mal. A vista escureceu, a respiração faltou e a dor no peito se tornou insuportável. A cada passo, ele sentia como se o pulmão fosse esmagado.A esposa correu em busca de ajuda, mas ouviu que ali só havia um pequeno posto de saúde. O hospital mais próximo ficava a quase três horas de distância de onde os dois estavam. No caminho, o braço esquerdo de Vanderlei começou a doer como se estivesse sendo atravessado por um ferro em brasa. O medo maior, no entanto, não era da morte. Era da esposa voltar para casa com ele em um caixão.No hospital, veio a confirmação: Vanderlei tinha sofrido um infarto. As artérias estavam quase totalmente obstruídas. Ele precisou passar por uma cirurgia de cateterismo às pressas. Foram mais de vinte dias internado, entre fisioterapias dolorosas, crises de choro e a sensação constante de que poderia não resistir. Tudo isso longe de casa, já que os dois estavam em Fortaleza, mas moram em São Paulo.O que o manteve de pé foi a presença da esposa. Ele não deixava que ela saísse nem por alguns minutos. Era a mão dela segurando a sua que lhe dava força para enfrentar cada procedimento, cada medo, cada madrugada gelada na UTI de hospital.Sete anos depois, Vanderlei ainda se emociona ao lembrar do que viveu. O infarto deixou cicatrizes físicas e emocionais, mas também mudou como ele enxerga a vida. Hoje, agradece por estar vivo e por ter sua esposa ao lado quando tudo parecia terminar. Ao olhar para trás, Vanderlei vê o quanto negligenciou sua saúde, sem ter uma rotina com alimentação saudável, exercícios e acompanhamento médico, e faz um alerta: saúde em primeiro lugar sempre!A história do Vanderlei é uma parceria do Histórias de ter.a.pia com a Novartis para a campanha #OVilãoDoSeuCoração para conscientização dos perigos do colesterol ruim.Saiba mais sobre o Vilão do Coração em saude.novartis.com.br/vilaodocoracao/#OVilaoDoSeuCoracao #SaúdeCardiovascular #Prevenção #ControleDoColesterol #CuideDoSeuCoração #PubliNovartis BR-36281

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review ESMO 2025's bladder cancer headlines, from the evolving role of PD-1/PD-L1 inhibitors to ctDNA-guided adjuvant therapy and antibody-drug conjugates redefining metastatic management.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped.  The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies.  Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve.   On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space.  BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next.   Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating. 

Wrapping up our live ESMO 2025 coverage from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review pivotal kidney cancer data, including RAMPART's results, emerging first-line combinations from KEYMAKER-U03 and more, offering a forward-looking view of where RCC research is heading next.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review the major ESMO 2025 prostate cancer studies, including ENZARAD, EMBARK, CAPItello-291, PSMAddition, and PR21. Together, they unpack their clinical impact and how evolving biomarkers, imaging, and treatment sequencing are redefining standards of care.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

O Making Of de hoje vai trazer os bastidores de uma campanha inspiradora que vem transformando o diálogo entre médicos e pacientes sobre o câncer de mama, que é a realidade de aproximadamente 74 mil mulheres todos os anos no Brasil, segundo o Instituto Nacional do Câncer (INCA). Estamos falando da campanha #MeuCaminho, iniciativa lançada pela Novartis, empresa líder global em medicamentos. A campanha tem um propósito muito especial: empoderar mulheres a assumirem o protagonismo em suas jornadas de tratamento, valorizando a informação, a escuta e a parceria com os profissionais de saúde.E para contar como essa campanha ganhou vida — da concepção à execução —, o nosso convidado é Sammy Schlesinger, Head de Comunicação e Relações com Pacientes da Novartis. Com mais de 20 anos de experiência em comunicação integrada e engajamento com o público, Sammy construiu uma carreira sólida, passando por empresas como Santander e Philips Healthcare, em posições locais, regionais e globais, com atuação no Brasil, América do Norte e Panamá.Desde 2023, ele está à frente da área de Comunicação e Relações com Pacientes da Novartis, liderando iniciativas que unem inovação, empatia e impacto social — pilares que também sustentam o sucesso da campanha #MeuCaminho..⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Assine a newsletter da Mega Brasil, a Direto da Redação⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.O programa Making Of é apresentado por Regina Antonelli todas as quartas, às 10h, com reapresentações diárias em mesmo horário e, aos finais de semana, às 15h, na ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rádio Mega Brasil Online⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. 

Today's guest is Scott Bradley, VP of AI and Innovation at Novartis. As the eighth largest pharmaceutical company in the world by revenue, Novartis' medicines reach millions of people worldwide. Their focus on the discovery and development of novel, breakthrough treatments sees them reimagining not just the delivery of said treatments, but the practice of medicine at large. Scott joins Emerj Editorial Director Matthew DeMello to examine how artificial intelligence is transforming trial design, operations, and patient engagement — while also reshaping industry trust and accountability. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Novartis' biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the $12 billion deal for Avidity in the context of Novartis' recent acquisitions and the antibody-oligonucleotide conjugate platform it is gaining.The team dives into RNA versus DNA modalities, noting antisense and siRNA approaches appear to be gaining traction with major pharmas as traditional gene therapy and gene editing approaches hit rocky times. Still, they note hopeful progress among base editing therapies given the promising early track records of over a dozen base editors in the clinic. They also discuss BioCentury's conversation with base editing inventor David Liu; Alkermes' $2.1 billion acquisition of Avadel; and β-catenin data from Parabilis. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657412#AntibodyOligonucleotideConjugates #RNAtherapeutics #BaseEditing #MuscularDystrophy #WntPathway #BetaCatenin #Orexin2Receptor #PrecisionMedicine00:01 - Sponsor Message: Evotec 02:04 - 12th China Healthcare Summit08:11 - Novartis' $12B Deal16:58 - Alkermes M&A20:01 - David Liu Base Editing25:02 - Parabilis' DataTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Swiss pharma giant Novartis sees Q3 income up by a quarter, allowing it to achieve its FY guidance and countering the fall in generic drug sales Stateside. BNP maintains its forecasts despite Q3 net income and revenue missing expectations. The French bank says it is determined to appeal a U.S. jury's verdict that ruled it breached sanctions on Sudan during the reign of President Omar al-Bashir. UK lender HSBC sees Q3 profits fall by 14 per cent on the back of legal provisions on a Bernie Madoff-related lawsuit. However, the bank still beat forecasts and hiked its net income guidance for the year.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

APAC stocks failed to sustain the momentum from the record highs on Wall St and were mostly subdued.US President Trump and Japanese PM Takaichi signed an agreement on the US-Japan alliance and framework for securing the supply of critical minerals and rare earths.European equity futures indicate a lower cash market open with Euro Stoxx 50 future down 0.2% after the cash market closed with gains of 0.6% on Monday.DXY is net negative amid gains in the JPY with USD/JPY slipping below the 152 mark post-Trump and Takaichi meeting.Global fixed income markets are broadly firmer. Crude has struggled for direction following the prior day's choppy performance.Looking ahead, highlights include German GfK (Nov), Richmond Fed (Oct), CaseShiller Home Prices (Aug), Consumer Confidence (Oct), ECB SCE (Sept), RBNZ's Richardson, Supply from Italy, UK, Germany & US.Earnings from Visa, Electronic Arts, PPG Industries, UnitedHealth, SoFi, PayPal, UPS, DR Horton, VF Corp, HSBC, BNP Paribas, Novartis, Logitech, Iberdrola & ASM International.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Mit eigenem KI-Chatbot, der dir alle Fragen rund ums Investieren beantwortet. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. https://www.whatsapp.com/channel/0029VaMpX3bDjiOUINh85d3P Milei-Sieg freut Finanzmärkte. Novartis kauft Avidity Biosciences. Peltz kauft Janus Henderson. Qualcomm macht KI-Chips. Keurig Dr Pepper wächst. HSBC hat Probleme wegen Madoff. Gerresheimer verbucht falsch. US-Bergbau fällt. T-Mobile US (WKN: A1T7LU) verkauft mehr Verträge mit Smartphones als in den letzten zehn Jahren und ist stärker als die Konkurrenz. Jetzt startet ein neuer CEO – wie ist seine Strategie? Der weltgrößte Hersteller von Zigarren und Pfeifentabak kommt aus Dänemark. Aber die Scandinavian Tobacco Group (WKN: A2AD2Q) wächst kaum noch. Rauchfreie Produkte sollen das Business beleben. Diesen Podcast vom 28.10.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Repasamos nombres como BNP Paribas, HSBC, Novartis, BASF y Symerise. Con Nicolás del Río, analista de Activotrade.

We bespreken met analist Jef Poortmans het aandeel van Novartis. De farmareus neemt biotechbedrijf Avidity over en ook Basic Fit sluit een stevige deal in Duitsland. In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie.  De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst.  Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen.  Onafhankelijk, relevant, telkens constructief en toekomstgericht.  Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

The real challenge for today's HR leaders isn't adopting AI, but ensuring people still feel seen, heard, and valued in a world shaped by it. Today's CHROs face a powerful question: how can we design organizations that are as human as they are high-performing? At Novartis, this challenge sparked a bold rethink of what it means to lead, grow, and belong. In this episode, Rob Kowalski, Chief People and Organization Officer at Novartis, shares how the company is reimagining HR through human-centered experiences that transform culture into a living system. He unpacks Novartis' Inspired, Curious, and Unbossed culture framework, the "behaviors in action" that make culture discussable, and programs like Future Me that redefine career growth through lattices instead of ladders. Rob also explores how storytelling connects every employee—scientists to HR teams—to patient impact, why leaders must balance empowerment with accountability, and how "unbossed" leadership is reshaping management itself. From AI coaching tools to redefining what growth and retention really mean, this conversation gives CHROs a fresh blueprint for building organizations that are truly human by design. ________________ Start your day with the world's top leaders by joining thousands of others at Great Leadership on Substack. Just enter your email: ⁠⁠https://greatleadership.substack.com/

US equity futures are indicating a higher open today. Europe markets have opened higher in early trades. And Asian markets have wrapped up the day higher almost everywhere as trade tensions around the world eased significantly. US and China finalized an outline trade agreement on Sunday, which has been the factor behind the positive sentiment. Japan's Nikkei broke through 50K for the first time in a broad rally. Taiex and Kospi also at fresh record highs.Companies mentioned: Plymouth Industrial REIT, Novartis, Avidity Biosciences, SoftBank, Sony, Warner Bros Discovery

The U.S. and China agree the framework of a trade deal with Presidents Trump and Xi Jinping due to meet later this week in South Korea. U.S. Treasury Secretary Scott Bessent says the move will help to dial down any further trade tensions between the two nations. Equity markets in Greater China have responded positively to the news while the Nasdaq is set to start the week 1 per cent higher. France has avoided a hat-trick of ratings agency downgrades, but Moody's has revised its forecast for the country to ‘negative', citing ongoing political turmoil and deficit fears. Swiss pharma giant Novartis has swooped for U.S. biotech firm Avidity in a $12bn cash deal.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über einen möglichen Handelsfrieden zwischen den USA und China, einen Mega-Deal im Biotech-Sektor und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um Novartis, Bayer, Avidity Biosciences, YPF, Banco Macro, BBVA Argentina, Apple, Amazon, Microsoft, Alphabet, Meta, Porsche Automobil Holding, Baidu, CRISPR THERAPEUTICS, Robinhood, Oklo, Uber, Siemens. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

Der Pharmakonzern Novartis will für rund 12 Milliarden US-Dollar das US-Unternehmen «Avidity Biosciences» kaufen. Novartis erhält dadurch Zugriff auf die sogenannte RNA-Technologie. Laut Stefan Schneider, Pharma-Analyst bei Vontobel, könnte durch den Zukauf eine effizientere Anwendung dazukommen. SMI -0.3%

Novartis möchte weiter in Gentechnologien investieren und kauft ein US-Unternehmen für 12 Mia. Dollar. "Eine gute Investition", nennt dies Stefan Schneider, Pharma-Analyst bei Vontobel.

Ever tried to escape work by picking up a hobby, only to discover it teaches you everything about your profession? In this fascinating conversation with Philip Atkinson, author of "BeeWise: 12 Leadership Lessons from Inside a Busy Hive," Cam and Otis explore how the complex world of beekeeping offers surprising insights into organizational leadership."I was looking in my private life to start a new hobby to do nothing to do with work," Philip explains about his beekeeping journey. "And it was all about complex organizations and decision making and communication and what the bees do. And of course, bang, it hit me. Beekeeping is a metaphor for complex life in working organizations today."From seasonal cycles that mirror business planning to colony division that reflects organizational scaling, Philip draws powerful parallels between the busy hive and today's workplace. "The bees have a natural survival instinct, and they need to adapt and grow," he shares, explaining how this translates to leadership challenges. "As a single leader, I can't do everything. I actually need to create an environment to scale things by trusting other people to be great."Whether you're fascinated by nature, looking for fresh leadership perspectives, or simply curious about how a hobby can transform into a life's purpose, this conversation offers rich insights into what we can learn from these remarkable creatures—or, as Philip would say, Apis Melifera.More About Philip:Philip Atkinson is a leadership coach, organizational transformation expert, and founder of Hive-Logic. With leadership roles at Novartis, Roche, Sanofi, and Publicis, Philip has worked with some of the world's largest organizations to build stronger teams and healthier cultures. Based near the Swiss border in France, he supports senior leaders across Europe and beyond through coaching, facilitation, and strategy. His warm, thought-provoking communication style has landed him features in Forbes, Management Today, CEO World, and BBC TV and radio. Philip is also a beekeeper. In his book Bee Wise: 12 Leadership Lessons from a Busy Beehive, he draws powerful insights from the hidden workings of the hive. The book explores decision-making, inclusion, communication, and purpose with contributions from global thought leaders at EY, L'Oréal, and more. All profits support Bees for Development, a charity helping families build sustainable livelihoods through beekeeping.#LeadershipLessons #BeekeepingAndBusiness #OrganizationalWisdom #HiveLogic #AdaptiveLeadership #Teamwork #NatureInspiredLeadership #LeadershipDevelopment #TribeAndPurpose #10xYourTeamChapter Times and Titles:From Corporate Life to Beekeeping [00:00 - 05:00]Introduction to Philip Atkinson and "BeeWise"The search for a hobby, "nothing to do with work"The moment of realization: "Beekeeping is a metaphor"Apis Melifera: More Than Just Bees [05:01 - 10:00]The fascinating terminology of beekeepingHow the beekeeping community responded to Philip's insightsInitial connections between hives and organizationsSeasonal Wisdom from the Hive [10:01 - 20:00]"Close some of the other projects first" - lessons in prioritizationThe bee lifecycle and seasonal changesHow nature's patterns inform business planningColony Division: A Model for Scaling [20:01 - 35:00]"The bees have a natural survival instinct."How colonies grow by dividing and multiplyingParallels to organizational growth and leadershipCreating an Environment for Others to Thrive [35:01 - 45:00]"As a single leader, I can't do everything."Trusting others to be greatBuilding systems that scale beyond individual capacityThe Busy Hive as Leadership Metaphor [45:01 - End]Key takeaways from Philip's bookHow to connect with Hive-LogicFinal thoughts on learning from nature

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Kann Regulierung neue Geschäftsfelder und Innovationen ermöglichen? Wie lassen sich Vorgaben wirksam in Unternehmen umsetzen?    In dieser Episode des The Agenda Podcasts spricht Dr. Klaus Moosmayer, Aufsichtsrat der Deutschen Bank AG und ehemaliger Vorstand bei Novartis sowie vorheriger Chief Compliance Officer bei Siemens, über die Herausforderungen und Chancen, die sich aus den sich wandelnden rechtlichen und regulatorischen Rahmenbedingungen in Europa ergeben. Zusammen mit Sherpany Podcast-Host Ingo Notthoff beleuchtet der Co-Vorsitzende des Global Future Council on Good Governance des Weltwirtschaftsforums die Bedeutung von Compliance und Risikomanagement für Unternehmen, die Balance zwischen Regulierung und Innovation sowie die spezifischen Herausforderungen, mit denen Unternehmen konfrontiert sind, wenn sie neue Vorschriften umsetzen. Zudem wird die Rolle von Vorständen und Aufsichtsräten bei der strategischen Governance thematisiert und wie Unternehmen sich auf die Umsetzung von EU-Vorgaben vorbereiten können.  Diese Impulse erhalten Sie in dieser Episode: Compliance ist mehr als nur Regeln – es geht um Werte Regulierung kann Innovationen sowohl fördern als auch behindern Ein ausgewogenes Regelsystem ist entscheidend für den Unternehmenserfolg Unternehmen müssen sich aktiv mit Regulierungen auseinandersetzen Die Kommunikation von Compliance-Regeln ist entscheidend Governance sollte nicht siloartig, sondern integriert sein Vorstände müssen eine Gesamtsicht auf Risiken haben Compliance als strategischer Hebel für Unternehmen Thank you for listening! Visit us at Sherpany.com or follow us on LinkedIn for board, board committee, and executive meetings solutions.

Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Novartis is among the world's leading pharmaceutical companies, pioneering data and advanced analytics in the pursuit of new medicines and patient outcomes. Xiong joins Emerj Editorial Director Matthew DeMello to examine how generative AI and foundation models are transforming R&D, clinical workflows, and research collaboration across the life sciences. The discussion highlights how domain-specific data strategies, improved data quality, and shared benchmarks are accelerating discovery and operationalizing AI for measurable ROI in biopharma. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments.   Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis.  (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis.   (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: ·       Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis,  an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease.  ·       Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems.  ·       Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios:   Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council.  Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø  “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025.   Ø  Treatment and Management of Psoriasis     Ø  Treatment and Management of Psoriatic Arthritis  

Send us a textIn this episode of WTR Small-Cap Spotlight, Dr. David Sans, healthcare investment banker, former Novartis oncology researcher, and long-time biotech strategist, joins host Tim Gerdeman, Vice Chair, Co-Founder, and Chief Marketing Officer of Water Tower Research, for an in-depth discussion on the state of the biotech industry. Together, they explore why optimism is returning to the sector, which technologies and therapeutic categories are leading the rebound, and how investment and IPO trends are shaping the next phase of biotech growth.  Discover the bullish underpinnings of The Wall Street Journal article last week titled “Why Biotech's Rally Can Last This Time”.

This Day in Legal History: Abrams v. United States ArguedOn October 21, 1919, the U.S. Supreme Court heard arguments in Abrams v. United States, a seminal case in the development of First Amendment jurisprudence. The case arose during the post–World War I Red Scare, when the government aggressively prosecuted speech perceived as dangerous or subversive. The defendants were Russian immigrants who distributed leaflets in New York City denouncing U.S. military intervention in the Russian Revolution and calling for a general strike. They were charged and convicted under the Sedition Act of 1918 for allegedly inciting resistance to the war effort.The Supreme Court upheld their convictions in a 7–2 decision, finding that the speech posed a “clear and present danger” to national security. However, it was Justice Oliver Wendell Holmes' dissent, joined by Justice Louis Brandeis, that left the most lasting impression. Holmes argued that only speech intended to produce imminent lawless action should be punished, introducing the enduring metaphor of the “marketplace of ideas” as essential to democratic deliberation.Legally, the case illustrates the government's ability to impose post-speech punishment—penalties after speech has occurred—as opposed to prior restraint, which involves preventing speech before it happens. The distinction is vital in American law: prior restraints are almost always unconstitutional, while post-speech sanctions may be permitted under narrow circumstances. In Abrams, the Court leaned toward deference to governmental wartime authority, but Holmes' dissent marked the beginning of a shift toward greater speech protections.The decision laid the groundwork for the more speech-protective standards adopted in later cases such as Brandenburg v. Ohio (1969). The post-speech punishment principle debated in Abrams remains a cornerstone of First Amendment law, highlighting the tension between state interests and individual liberties in times of political conflict.When two alleged drug traffickers survived a U.S. military strike in the Caribbean, the Trump administration immediately repatriated them rather than detain them — a decision that reveals a troubling logic behind the president's new “war” on narco‑terrorism. The administration has declared the campaign a “non‑international armed conflict,” but legal experts note that this classification offers no real authority for military detention. In other words, the United States can kill suspects under this self‑declared war framework, but it has no clear legal footing to hold survivors.Experts said the administration likely chose the least damaging option: send the survivors home and avoid a courtroom. Detaining them at Guantanamo or on U.S. soil would have triggered habeas corpus challenges, forced disclosure of evidence, and risked exposing the strikes as legally indefensible. One former State Department lawyer said any trial would have “undermined the narrative” that the attacks were lawful military operations. By refusing to hold prisoners, the administration sidesteps both judicial scrutiny and transparency.The result is a perverse incentive structure. If survivors are released but detainees are liabilities, the easiest path for officials is to ensure there are no survivors at all. The legal asymmetry—where killing is simpler than capture—encourages tactics that maximize lethality while minimizing accountability. As a result, Trump's “drug war” risks becoming less about law enforcement and more about ensuring that no one lives long enough to challenge the legality of U.S. actions.In Trump's drug war, prisoners may be too much of a legal headache, experts say | ReutersGlobal pharmaceutical companies are rapidly ramping up U.S. manufacturing in response to a looming Trump administration policy that would impose 100% tariffs on imported branded and patented drugs. While enforcement is delayed for companies that commit to domestic investment, the threat has already triggered a wave of fast-tracked spending, direct-to-consumer sales shifts, and pricing concessions in exchange for temporary tariff exemptions.Major players like Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly, and Roche have pledged tens of billions of dollars to build or expand plants across the U.S. to shield themselves from future penalties. Some, like Pfizer and AstraZeneca, secured multi-year tariff exemptions by agreeing to pricing deals and participation in the administration's new TrumpRx.gov program. Others, like Novartis and Sanofi, are spreading investments across multiple states and sites, creating thousands of jobs as part of their strategic insulation.The tariff threat is driving a major reshaping of global supply chains and investment strategies, as companies aim to avoid the legal and financial burden of import duties by domesticating both manufacturing and distribution. While some firms say they are already well-positioned with sufficient U.S. inventory, the broader trend reflects a defensive industry-wide shift to preemptively comply with the administration's protectionist push.Global drugmakers rush to boost US presence as tariff threat looms | ReutersTrevor Milton, the disgraced founder of electric-truck startup Nikola, is somehow back as a CEO—this time leading SyberJet Aircraft, a private jet manufacturer, according to reporting by Techdirt. Milton was convicted of fraud for deceiving investors about Nikola's technology, most famously releasing a misleading video of a prototype truck that was actually rolling downhill, not self-propelled. He was sentenced to four years in prison but never served a day, thanks to a pardon from Donald Trump earlier this year—reportedly after donating millions to Trump-aligned causes and hiring the brother of current Attorney General Pam Bondi as his attorney.Now, just months after that pardon, Milton has been tapped to lead development of a new high-speed jet for SyberJet, with promised performance metrics that already sound suspiciously ambitious. The company, privately backed, won't need to answer to public shareholders—but it will still need investor trust to raise money for a jet not slated for delivery until 2032. TechDirt points out how the company's promotional material leans into rewriting Milton's history, calling him “renowned” rather than acknowledging the full scope of his fraudulent past.The piece underscores a broader theme of “failing upward,” highlighting how white-collar offenders, especially white men with political connections, often land on their feet despite serious criminal convictions–and has some interesting implications for the future career of George Santos. Milton's quick rebound from federal fraud conviction to C-suite leadership is less an exception than a reminder of how accountability gaps persist in American corporate culture.Convicted Fraudster Trevor Milton Rides His Trump Pardon To Another CEO Job, Somehow | TechdirtIn my column for Bloomberg this week, I dive in to the governor's race in my home state. The 2025 New Jersey gubernatorial race has become a tax-policy showdown between Jack Ciattarelli and Mikie Sherrill—both of whom are framing affordability as their central mission, but doing so with deeply flawed approaches. Ciattarelli is offering aggressive tax cuts and structural overhauls that are, frankly, reckless in a state with a delicate and complicated fiscal ecosystem. His plan to flatten income tax brackets and slash corporate rates isn't just optimistic—it's ahistorical. We've seen this movie before in Kansas, where sweeping tax cuts led to revenue collapse, credit downgrades, and bipartisan regret. Ciattarelli is essentially proposing a rerun, but with no clearer escape plan if it fails.Sherrill, by contrast, is pragmatic to the point of inertia. Her emphasis on municipal service sharing and administrative tweaks is fine as far as it goes—but it doesn't go very far. Her promise to freeze utility rates via emergency powers, for instance, isn't just legally questionable, it also misdiagnoses the issue: state governments don't control wholesale energy prices. It's a symbolic gesture dressed up as policy.Neither candidate seems willing to address the structural drivers of New Jersey's notoriously high property taxes, preferring instead to nibble around the edges or promise caps that could backfire. That's a missed opportunity. As I argue in the column, New Jersey doesn't need sweeping cuts or more bureaucratic tinkering—it needs targeted relief for the people who actually feel the pinch. Expanding the state Earned Income Tax Credit and implementing a robust child tax credit would offer immediate, evidence-backed help to those struggling most with affordability. These aren't radical ideas; they're already working in other states.Ciattarelli's plan is built on trickle-down economics and wishful math. Sherrill's is built on competent management, but lacks ambition. The voters deserve more than either of those options.Tax Platforms in NJ Governor's Race Leave Out the Best Ideas This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Podcast: Demand Better from Wearable Technology feat. Marco Benitez________________________________________Guest Overview• Marco Benitez: CEO and co-founder of ROOK; former Tae Kwon Do national champion; biomedical engineer with experience at Roche and Novartis; serial entrepreneur with a passion for using technology to make healthcare data more accessible and actionable.________________________________________Episode Highlights & Key Points• The Problem with Wearable Technology: Marco discusses the current fragmentation in the wearable tech industry—there are hundreds of devices, each with their own data formats and APIs, making it tough for healthcare, wellness, and insurance companies to get a true picture of a person's health.• ROOK's Mission: The company was founded to solve this exact problem. ROOK offers a unified API that connects data from over 400 wearable devices and health apps, allowing companies to pull standardized health metrics and deliver more personalized, preventive care.• Marco's Personal Journey: From growing up in Mexico to winning national Tae Kwon Do championships, Marco shares how discipline, resilience, and curiosity guided him into biomedical engineering and eventually to high-profile roles in pharma—where he saw the huge potential (and gaping holes) in health data integration.• Bridging the Gap: From Data to Action: Marco explains that raw data from devices is only valuable if it's accurate, standardized, and easily accessible. ROOK's platform makes it easy for companies to integrate wearable data into their apps, research, or wellness programs without having to build separate integrations for each device.• Impact on Healthcare and Insurance: With better, real-time health data, organizations can validate and predict user behavior, improve engagement, and help people take more meaningful action toward their health goals.• Data Privacy and Security: Marco emphasizes that ROOK is built to the highest standards of privacy and reliability, ensuring sensitive health information is protected while still being usable for better care and outcomes.• Vision for the Future: Marco sees wearable data and unified APIs as key to unlocking a world where healthcare is more predictive, personalized, and preventive. He believes ROOK's approach will drive the industry toward more human-centered, data-driven wellness solutions.________________________________________Notable Quotes & Insights• “Health data has the power to improve lives—but only if it's accurate, standardized, and accessible.”• Marco's journey is as much about personal growth and perseverance as it is about technology: “Discipline and resilience are what translate across sports, engineering, and entrepreneurship.”________________________________________Why ROOK Matters• ROOK is setting new standards by making health data integration seamless, helping companies and individuals benefit from the full power of wearable technology.• The platform is already helping clients in healthcare, wellness, and insurance make smarter, more impactful decisions with real-time health metrics.________________________________________Useful Links• Learn more about ROOK: https://www.tryrook.io/ • Connect with Marco Benitez on LinkedIn: https://www.linkedin.com/in/marcobzg/ ________________________________________Want to create live streams like this? Check out StreamYard: https://streamyard.com/pal/d/5353468462366720

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody-drug conjugate, Datroway, demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head-to-head trial involving Trop2-targeted therapies. This reflects the increasing focus on antibody-drug conjugates as precision medicine tools that offer targeted treatment options with potentially improved outcomes over traditional chemotherapy.In a move highlighting the ongoing trend of bolstering domestic production capacities, Merck is making a substantial $3 billion investment in a small molecule drug plant in Virginia. This is part of a broader $70 billion commitment to expand manufacturing and R&D capabilities in the U.S. Such strategic investments are crucial for maintaining competitive advantage and ensuring drug availability while meeting rising demands and streamlining supply chains.Turning to regulatory updates, the FDA has approved Amgen and AstraZeneca's Tezspire for chronic rhinosinusitis with nasal polyps. This marks Tezspire's second indication, following its initial approval for severe asthma in 2021. The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent.In oncology, Merck's Keytruda and Astellas/Pfizer's Padcev have made headlines with compelling results in muscle-invasive bladder cancer. The combination therapy reduced the risk of death by 50%, reinforcing Keytruda's position as a cornerstone immunotherapy across multiple cancer types. This result not only augments treatment options but also signifies the potential for combination regimens to enhance patient outcomes.Roche has expanded the indication of its aging oncology drug Gazyva to treat lupus nephritis, demonstrating strategic repurposing efforts to extend the lifecycle of existing therapies. While this expansion into autoimmune diseases comes late in Gazyva's lifecycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas.AstraZeneca and Daiichi Sankyo's Enhertu showed robust efficacy in early breast cancer treatment, potentially reshaping therapeutic strategies by offering new hope for early intervention. Similarly, Novartis' Pluvicto demonstrated promise in slowing hormone-sensitive prostate cancer progression, underscoring the potential of radioligand therapies in oncology.However, not all developments have been positive. AstraZeneca faced setbacks when its Imfinzi and Lynparza combination failed to meet survival goals in ovarian cancer, underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the FDA.The industry is also witnessing significant advancements in next-generation ADCs, as evidenced by Tubulis' 59% response rate in early clinical trials, which has attracted substantial investor interest. Additionally, Grail's Galleri cancer blood test is progressing towards FDA review with enhanced performance data, potentially revolutionizing cancer screening and early detection practices.These scientific and regulatory milestones are complemented by strategic investments in bioconjugation technologies. Cohance Life Sciences' $10 million investment in NJ Bio to enhance GMP bioconjugation capabilities exemplifies this trend. Such investments are crucial for advancing ADC development, which remains a focal point for innovative cancer therapies.Overall, these developments reflect a dynamic phase for the pharmaceutical and biotech sectors characterized by signSupport the show

In this episode of SCW for Pharma host Evren Ozkaya welcomes Katja Lumbar Globocnik, Head of U.S. Supply Chain at Exeltis and Xiromed, subsidiaries of Insud Pharma. Katja brings decades of experience across global pharmaceutical supply chains, from her early days in Europe with companies like Novartis and Sandoz to leading countless generic product launches at Teva in the United States.Evren and Katja open their discussion by comparing the dynamics of large versus small-to-mid-sized pharma companies. Katja explains how larger organizations, while rich in structure and learning opportunities, can be slowed by bureaucracy. In contrast, smaller companies operate with greater agility, allowing individuals to take broader ownership of decisions and execution. This leaner environment, she notes, cultivates problem solvers.The conversation then turns to digitalization and system maturity. Contrary to expectations, Katja argues that size doesn't guarantee sophistication. Many large companies still rely on traditional operations, while smaller firms like Insud Pharma have adopted advanced technologies, including AI-driven analytics and automation. These tools, she explains, are transforming supply chains by accelerating decision-making, enabling real-time visibility, and automating repetitive tasks.Evren and Katja also examine the management of operational excellence in multi-site environments. Katja sees clear value in driving OpEx globally, while acknowledging the growing trend toward regionalization. Together, they emphasize the importance of balancing standardization with local flexibility—especially as cloud-based systems make real-time benchmarking and performance tracking across sites possible.When discussing product launches, Katja highlights the excitement and challenges of bringing generic medicines to market. Success, she says, depends on teamwork, scenario planning, and calm risk assessment—particularly in the U.S., where speed to market is critical.Finally, the discussion circles back to digital transformation at manufacturing sites. Katja identifies alignment, investment constraints, and resistance to transparency as common barriers. Still, she believes progress is inevitable, led by plant leaders who take a holistic view, embrace visibility, and see weaknesses as opportunities for improvement.Evren closes by asking Katja what advice she would give her younger self. Her answer is simple and powerful: “Be fearless. Learn as much as you can. Go for it until someone stops you.”

Hot off the press in the Presidential Plenary at #ESMO25, we chat with Dr Scott Tagawa (Weill-Cornell, USA) about the positive data he just presented from the PSMAddition trial. This is an eagerly awaited phase III randmosied trial of patients with mHSPC, to see if the addition of six cycles of Lu-PSMA-617 to a control arm of ADT and an ARPI, could improve rPFS and other endpoints. We are also joined in the studio by Prof Michael Hofman (Peter MacCallum Cancer Centre, AUS), co-PI of the UpFront PSMA trial which also explored a similar concept, plus some comments from our other colleague, prof Arun Azad, who was the Discussant in the Presidential at ESMO25. Declan Murphy hosting GU Cast solo today while Renu Eapen was in the OR doing surgery. Even better on our YouTube channelThis is a Themed Podcast supported by our Silver Partners, Novartis.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of fascinating updates that underscore a period of significant scientific advancement, strategic partnerships, and regulatory developments in the industry.Starting with Dianthus Therapeutics, which has taken a bold step by investing up to $1 billion to license a bifunctional fusion protein from Nanjing Leads Biolabs. This protein targets autoimmune disorders, a field of immense interest due to the unmet medical needs and potential for breakthrough treatments. Such substantial financial commitments highlight the ongoing trend in the biotech sector towards innovative therapies for autoimmune diseases. In parallel, Sanofi has secured a $500 million agreement with Evoq Therapeutics, continuing its strategic focus on next-generation autoimmune technologies. This partnership aligns with Sanofi's broader strategy to leverage cutting-edge science in managing autoimmune conditions more effectively. Sanofi's engagement with Evoq Therapeutics stands out as a significant step forward in conquering autoimmune diseases through nanodisc technology designed to facilitate the development of curative treatments for disorders like celiac disease and type 1 diabetes. This collaboration reflects a growing trend among pharmaceutical giants investing in advanced biotechnologies that promise transformative impacts on disease management and patient care.Meanwhile, AstraZeneca's renewed collaboration with Immunai, valued at $85 million, seeks to enhance therapies for inflammatory bowel disease through artificial intelligence. This collaboration is part of a wider industry movement towards utilizing AI in drug discovery and development, particularly for complex diseases like IBD. AI's ability to process large datasets and identify potential therapeutic targets faster and more accurately is revolutionizing how companies approach drug development.In clinical trial news, Praxis Precision Medicines has reported positive Phase 3 results for ulixacaltamide in treating essential tremor. This outcome reverses prior concerns from interim analyses and illustrates the persistent innovation in neurological disorder treatments. Similarly, AiCuris has announced successful results from its Phase 3 trial of pritelivir for refractory herpes simplex virus infections in immunocompromised patients. This success paves the way for an FDA filing, demonstrating ongoing progress in antiviral therapy development.Novartis is also making strides with favorable outcomes from its Phase 3 trial of fabhalta for IgA nephropathy. As a complement factor B inhibitor, fabhalta has shown efficacy in slowing kidney function decline, which may lead to a new standard of care for this chronic kidney disease. Novartis plans to file these findings with regulatory bodies soon, highlighting its strategic focus on diversifying into rare kidney diseases.Turning to industry trends, there is significant investment activity in antibody-drug conjugates (ADCs). French biotech company ADCytherix has raised $122 million to advance these targeted therapies into clinical trials. ADCs are gaining traction due to their precision in targeting cancer cells while minimizing damage to healthy tissues. Such advancements signal a potential shift in cancer treatment paradigms toward more targeted and less toxic therapies. Similarly, Tubulis raised an impressive Series C funding round to advance work on ADCs targeting ovarian and lung cancers, underscoring the growing interest in the potential of ADCs engineered to deliver cytotoxic drugs specifically to cancer cells.In another intriguing development, research has shown that a common diabetes drug can alleviate brain inflammation in female mice with multiple sclerosis. This finding exemplifies the growing interest in drug repurposSupport the show

In this episode of, "Empowered Intimacy: Getting Your Sexy Back After Breast Cancer," we open up an important conversation about sexual health after a breast cancer diagnosis. Melissa is joined by her friend Deltra, a mom of five living with triple-negative metastatic breast cancer, and Dr. Laila Agrawal, a board-certified medical oncologist dedicated to putting sexual health at the forefront of cancer care. Many carry these concerns silently, but intimacy is an important part of quality-of-life care. Together, they share personal stories, explore why this topic is often overlooked, and offer practical tips for starting the conversation with your doctor, asking the right questions, and advocating for the support and resources that you deserve. Special thanks to Lilly, Merck, and Novartis for supporting the Cancer Fashionista Foundation and making this episode possible.

Investing in health and science research isn't just about curing diseases. It has huge impacts across society, from creating jobs to driving economic growth to boosting national competitiveness. Study shows that every $ invested in the life sciences industry generates $3 in GDP globally, whereas every job created in the life sciences industry generates five in the global economy. Life sciences are one of the most powerful engines of prosperity, yet many governments still underestimate their economic return.In this episode of The Ripple Effect: Investing in Life Sciences, host Dan Riskin speaks with Patrick Horber, President of Novartis International, and David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. Together, they break down the outsized economic impact of life science innovation, from trillions in US bioscience output to China's meteoric rise as a global R&D hub. The conversation delves into the ways governments can support innovation with not just money, but through policy and regulation; plus, some of the best ways that countries can help the sector secure investment, talent, and long-term growth.This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Host: Dan RiskinGuests: Patrick Horber, David Gluckman  Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to Building Brand You™, the podcast that helps you accelerate your success by unlocking your greatest asset – you.   KEY TAKEAWAYS In Latin, the word confidence means trust. The quality of internal dialogue will determine the quality of the dialogue with every external stakeholder in your life. Let fear be your counsel and not your jailer. Life is lived forward and understood backwards.  “Our deepest fear is not that we are inadequate. Our deepest fear is that we are powerful beyond measure. It's our light, not our darkness that frightens us.” Marianne Williamson, RESOURCES MENTIONED: Self Esteem & Peak Performance by Jack Canfield - https://www.amazon.com/Self-Esteem-Peak-Performance-Canfield/dp/1933328010 A Return to Love: Reflections on the Principles of "A Course in Miracles" by Marianne Williamson - https://www.amazon.com/Return-Love-Reflections-Principles-Miracles/dp/0060927488 What Got You Here Won't Get You There: How Successful People Become Even More Successful by Marshall Goldsmith - https://www.amazon.com/What-Got-Here-Wont-There/dp/0739342231 60 Life-Changing Lessons in 60 Weeks by Peter Milligan - https://www.sixtylessons.com/    ABOUT OUR GUEST: Peter is an inspirational speaker and business psychologist with 30 years' experience. He helps business leaders and teams to have less stress, more joy and greater productivity. Originally an IT professional, Peter retrained in psychology and joined the management team of a leading Australian HR consulting firm. After moving to the UK in 2000, he became a director of Europe's largest executive coaching firm before establishing his own business in 2005.  Peter's clients have ranged from professional services firms, SMEs and family businesses to larger organisations including Australia Post, BP, Credit Suisse, Kerry Foods, Novartis, Oxford University, Rolls-Royce, and Vodafone. CONNECT WITH PETER MILLIGAN: Linkedin - www.linkedIn.com/in/petermilligan Website - https://www.newgenerationleaders.com/ Email - peter.milligan@newgenleaders.com Website - https://www.sixtylessons.com/Twitter - https://twitter.com/PeterMilligan Facebook - https://www.facebook.com/peter.milligan.777     ABOUT KYM HAMER: Kym is an international leadership and personal branding thought leader, an executive coach, and a programme design and facilitation practitioner. She is also the creator of Building Brand You™ - a methodology helping organisations, teams, and individuals to build reputation, presence, and gravitas. Kym works with leaders - both individually and in organisational development initiatives - to inspire and engage thinking styles and behaviour that achieve results and leave legacy. In 2020, just one year after launching her business, she was nominated by Thinkers360 as one of the Top 100 Women B2B Leadership influencers and is currently in the Top 15 Personal Branding and Top 10 Marketing Influencers in the world. For 5 years running Kym has also been one of Thinkers360's Top 10 Thought Leaders on Entrepreneurship and in 2023, 2024 and 2025, was recognised as one of their Top Voices globally. She has been part of Homeward Bound Projects faculty since 2020, a global initiative reaching 1.8 billion people, equipping women and non-binary people with a STEMM background to lead conversations for a sustainable future. She is currently the Program Design and Faculty Lead for the 10th on-line cohort and was part of the on-board faculty who voyaged to Antarctica in 2023 and 2025, to deliver the initiative's immersive component. In between all of these things, you'll find her curled up in a corner with her nose in a book.   Building Brand You™: JOIN the BBY Facebook Group - https://www.facebook.com/groups/buildingbrandyou SUBSCRIBE to the BBY Podcast on: (Apple) - https://podcasts.apple.com/gb/podcast/building-brand-you/id1567407273 (Spotify) - https://open.spotify.com/show/4Ho26pAQ5uJ9h0dGNicCIq CONNECT WITH KYM HAMER: LinkedIn - https://linkedin.com/in/kymhamer/ Facebook - https://www.facebook.com/kymhamerartemis/ TikTok - https://www.tiktok.com/@kymhamer Thinkers360 - https://bit.ly/thinkers360-kymhamer-BBY Find out about BBY Coaching - https://calendly.com/kymhamer/bbychat/   HOSTED BY: Kym Hamer   DISCLAIMER: The views, information, or opinions expressed during the Building Brand You™ podcast series are solely those of the individuals involved. They do not necessarily represent any other entities, agencies, organisations, or companies. Building Brand You™ is not responsible and does not verify the accuracy of any of the information in the podcast available for listening on this site. The primary purpose of this podcast is to educate and inform. This podcast does not constitute legal advice or services  

Investing in health and science research isn't just about curing diseases. It has huge impacts across society, from creating jobs to driving economic growth to boosting national competitiveness. Study shows that every $ invested in the life sciences industry generates $3 in GDP globally, whereas every job created in the life sciences industry generates five in the global economy. Life sciences are one of the most powerful engines of prosperity, yet many governments still underestimate their economic return.In this episode of The Ripple Effect: Investing in Life Sciences, host Dan Riskin speaks with Patrick Horber, President of Novartis International, and David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. Together, they break down the outsized economic impact of life science innovation, from trillions in US bioscience output to China's meteoric rise as a global R&D hub. The conversation delves into the ways governments can support innovation with not just money, but through policy and regulation; plus, some of the best ways that countries can help the sector secure investment, talent, and long-term growth.This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Host: Dan RiskinGuests: Patrick Horber, David Gluckman  Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery of the immunotherapy. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center. I am also the editor-in-chief of the Educational Book. Bispecific antibodies represent an innovative and advanced therapeutic platform in hematologic and solid tumors. And today, I am delighted to be joined by Dr. Giuseppe Curigliano to discuss the current landscape of bispecific antibodies and their potential to reshape the future of precision oncology. Dr. Curigliano was the last author of an ASCO Educational Book piece for 2025 titled, "Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances." Dr. Curigliano is a breast medical oncologist and the director of the Early Drug Development Division and chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan. He is also a full professor of medical oncology at the University of Milan. You can find our disclosures in the transcript of this episode. Dr. Curigliano, Giuseppe, welcome and thanks for being here. Dr. Giuseppe Curigliano: Thanks a lot for the invitation. Dr. Hope Rugo: Giuseppe, I would like to first ask you to provide some context for our listeners on how these novel therapeutics work. And then perhaps you could tell us about recent developments in the field of bispecific antibodies for oncology. We are at a time when antibody-drug conjugates (ADCs) are all the rage and, trying to improve on the targeting of specific antigens, proteins, receptors in the field of oncology is certainly a hot and emerging topic. Dr. Giuseppe Curigliano: So, thanks a lot. I believe really it was very challenging to try to summarize all the bispecific antibodies that are under development in multiple solid tumors. So, the first thing that I would like to highlight is the context and the mechanism of action of bispecific antibodies. Bispecific antibodies represent a groundbreaking advancement in cancer immunotherapy, because these engineered molecules have the unique ability to target and simultaneously bind to two distinct antigens. That is why we call them bispecific. So typically, one antigen is expressed on the tumor cell and the other one is expressed on the immune effectors, like T-cell or natural killer cells. So this dual targeting mechanism offers several key advantages over conventional monoclonal antibodies because you can target at the same time the tumor antigen, downregulating the pathway of proliferation, and you can activate the immune system. So the primary mechanism through which bispecific antibodies exert their therapeutic effects are: First, T-cell redirecting. I mean, many bispecific antibodies are designed to engage tumor-associated antigens like epidermal growth factor receptor, HER2, on the cancer cell and a costimulatory molecule on the surface of T-cell. A typical target antigen on T-cell is CD3. So what does it mean? That you activate the immune system, immune cells will reach the tumor bed, and you have a dual effect. One is downregulating cell proliferation, the other one is activation of the immune system. This is really important in hematological malignancies, where we have a lot of bispecifics already approved, like acute lymphoblastic leukemia or non-Hodgkin lymphoma.  The second, in fact, is the engagement of the tumor microenvironment. So, if you engage immune effector cells like NK cells or macrophages, usually the bispecific antibodies can exploit the immune system's ability to recognize and kill the immune cells, even if there is a lack of optimal antigen presentation.  And finally, the last mechanism of action, this may have a role in the future, maybe in the early cancer setting, is overcoming immune evasion. So bispecific antibodies can overcome some of the immune evasion mechanisms that we see in cancer. For example, bispecific antibodies can target immune checkpoint receptors, like PD-L1 and CTLA-4. Actually, there is a bispecific under development in breast cancer that has a dual targeting on vascular endothelial growth factor receptor and on PD-L1. So you have a dual effect at the same time. So, what is really important, as a comment, is we need to focus first on the optimal format of the bispecific, the optimal half-life, the stability, because of course even if they are very efficient in inducing a response, they may give also a lot of toxicities. So in clinical trials already, we have several bispecifics approved. In solid tumors, very few, specifically amivantamab for non-small cell lung cancer, but we have a pipeline of almost 40 to 50 bispecifics under development in multiple solid tumors, and some of them are in the context of prospective randomized trials. Dr. Hope Rugo: So this is really a fascinating area and it's really exciting to see the expansion of the different targets for bispecific antibodies. One area that has intrigued me also is that some of the bispecifics actually will target different parts of the same receptor or the same protein, but presumably those will be used as a different strategy. It's interesting because we have seen that, for example, in targeting HER2. Dr. Giuseppe Curigliano: Oh, yes, of course. You may consider some bispecifics like margetuximab, I suppose, in which you can target specifically two different epitopes of the same antigen. This is really an example of how a bispecific can potentially be more active and downregulating, let us say, a pathway, by targeting two different domains of a specific target antigen. This is an important point.  Of course, not all the bispecifics work this way, because some of the target antigen may dimerize, and so you have a family of target antigen; an example is epidermal growth factor receptor, in which you have HER1, HER2, HER3, and HER4. So some of them can inhibit the dimerization between one target antigen and the other one, in order to exert a more antiproliferative effect. But to be honest, the new generation of them are more targeting two different antigens, one on the tumor and one on the microenvironment, because according to the clinical data, this is a more efficient way to reduce proliferation and to activate the immune system. Dr. Hope Rugo: Really interesting, and I think it brings us to the next topic, which is really where bispecific antibodies have already shown success, and that is in hematologic malignancies where we have seen very interesting efficacy and these are being used in the clinic already. But the expansion of bispecific antibodies into solid tumors faces some key challenges. It's interesting because the challenges come in different shapes and forms. Tell us about some of those challenges and strategies to optimize bispecific antibody design, delivery, patient selection, and how we are going to use these agents in the right kind of clinical trials. Dr. Giuseppe Curigliano: This is really an excellent question because despite bispecific antibodies having shown a remarkable efficacy in hematological malignancies, their application in solid tumors may have some challenges. The first one is tumor heterogeneity. In hematological malignancy, you have a clear oncogene addiction. Let us say that 90% of the cells may express the same antigen. In solid tumors, it is not the same. Tumor heterogeneity is a typical characteristic of solid tumors, and you have high heterogeneity at the genetic, molecular, and phenotypic levels. So tumor cells can differ significantly from one another, even if within the same tumor. And this heterogeneity sometimes makes it difficult to identify a single target antigen that is universally expressed in an hematological malignancy. So furthermore, sometimes the antigen expressed on a tumor cell can be also present on the normal tissue. And so you may have a cross-targeting. So let's say, if you have a bispecific against epidermal growth factor receptor, this will target the tumor but will target also the skin with a lot of toxicity. The second challenge is the tumor microenvironment. The solid tumor microenvironment is really complex and often immunosuppressive. It is characterized by the presence of immunosuppressor cells like the T regulators, myeloid derived suppressor cells, and of course the extracellular matrix. All these factors hinder immune cell infiltration and also may reduce dramatically the effectiveness of bispecific antibodies. And as you know, there is also an hypoxic condition in the tumor. The other challenge is related to the poor tumor penetration. As you know also with antibody-drug conjugate, only 1 to 3% of the drug will arrive in the tumor bed. Unlike hematological malignancies where tumor cells are dispersed in the blood and easily accessible, the solid tumors have a lot of barriers, and so it means that tumor penetration can be very low. Finally, the vascularity also of the tumor can be different across solid tumors. That is why some bispecifics have a vascular endothelial growth factor receptor or vascular endothelial growth factor as a target. Of course, what do we have to do to overcome these challenges? First, we have to select the optimal antigen. So knowing very well the biology of cancer and the tumor-associated antigens can really select a subgroup of epitopes that are specifically overexpressed in cancer cells. And so we need to design bispecifics according to the tumor type. Second, optimize the antibody format. So there are numerous bispecific antibody formats. We can consider the dual variable domain immunoglobulin, we specified this in our paper. The single chain variable fragments, so FC variable fragments, and the diabodies that can enhance both binding affinity and stability. And finally, the last point, combination therapies. Because bispecific antibodies targeting immune checkpoint, we have many targeting PD-1 or PD-L1 or CTLA-4, combined eventually with other immune checkpoint inhibitors. And so you may have more immunostimulating effect. Dr. Hope Rugo: This is a fascinating field and it is certainly going to go far in the treatment of solid tumors. You know, I think there is some competition with what we have now for antibody-drug conjugates. Do you see that bispecifics will eventually become bispecific ADCs? Are we going to combine these bispecific antibodies with ADCs, with chemotherapy? What is the best combination strategy do you think looking forward? Dr. Giuseppe Curigliano: So, yes, we have a bispecific ADC. We have actually some bispecifics that are conjugated with a payload of chemotherapy. Some others are conjugated with immunoactivation agents like IL-2. One of the most effective strategies for enhancing bispecific activity is the combination therapy. So which type of combination can we do? First, bispecific antibodies plus checkpoint inhibitors. If you combine a bispecific with an immune checkpoint, like anti-PD-1, anti-PD-L1, or anti-CTLA-4, you have more activity because you have activation of T-cells, reduction of immunosuppressive effect, and of course, the capability of this bispecific to potentiate the activity of the immune checkpoint inhibitor. So, in my opinion, in a non-small cell lung cancer with an expression of PD-L1 more than 50%, if you give pembrolizumab plus a bispecific targeting PD-L1, you can really improve both response rate and median progression-free survival.  Another combination is chemotherapy plus bispecific antibodies. Combining chemotherapy with bispecific can enhance the cytotoxic effect because chemotherapy induces immunogenic cell death, and then you boost with a bispecific in order to activate the immune system. Bispecific and CAR T-cells, until now, we believe that these are in competition, but this is not correct. Because CAR T-cells are designed to deliver an activation of the immune system with the same lymphocytes engineered of the patients, with a long-term effect. So I really do not believe that bispecifics are in competition with CAR T-cells because when you have a complete remission induced by CAR T-cell, the effect of this complete remission can last for years. The activity of a bispecific is a little bit different. So there are some studies actually combining CAR T-cells with bispecifics. For example, bispecific antibodies can direct CAR T-cells in the tumor microenvironment, improving their specificity and enhancing their therapeutic effect.  And finally, monoclonal antibody plus bispecific is another next generation activity. Because if you use bispecific antibodies in combination with existing monoclonal antibodies like anti-HER2, you can potentially increase the immune response and enhance tumor cell targeting. In hematological malignancies, this has been already demonstrated and this approach has been particularly effective. Dr. Hope Rugo: That's just so fascinating, the whole idea that we have these monoclonal antibodies and now we are going to add them to bispecifics that we could maybe attach on different toxins to try and improve this, or even give them with different approaches. I suppose giving an ADC with a bispecific would sort of be similar to that idea of giving a monoclonal antibody with the bispecific. So it is certainly intriguing. We also will need to understand the toxicity and cost overall and how we are going to use these, the duration of treatment, the assessment of biomarkers. There are just so many different aspects that still need to be explored.  And then with that idea, can you look ahead five or ten years from now, and tell us how you think bispecific antibodies will shape our next generation cancer therapies, how they will be incorporated into precision oncology, and the new combinations and approaches as we move forward that will help us tailor treatment for patients both with solid tumors and hematologic malignancies? Are we going to be giving these in early-stage disease in solid tumors? So far, the studies are primarily focusing on the metastatic setting, but obviously one of the goals when we have successful treatments is to move them into the early stage setting as quickly as possible. Dr. Giuseppe Curigliano: Let us try to look ahead five years rather than ten years, to be more realistic. So, personally I believe some bispecifics can potentially replace current approaches in specifically T-cell selected population. As we gather more data from ongoing clinical trials and we adopt a deeper understanding of the tumor immuno microenvironment, of course we may have potentially new achievement. A few days ago, we heard that bispecifics in triple negative breast cancer targeting VEGF and PD-L1 demonstrated an improvement in median progression-free survival.  So, how to improve and to impact on clinical practice both in the metastatic and in the early breast cancer setting or solid tumor setting? First, personalized antigen selection. So we need to have the ability to tailor bispecific antibody therapy to the unique tumor profile of individual patients. So the more we understand the biology of cancers, the more we will be able to better target. Second, bispecific antibodies should be combined. I can see in the future a potential trial in which you combine a bispecific anti-PD-L1 and VEGF with immune checkpoint inhibitor selected also to the level of expression of PD-L1, because integration of antibody bispecific with a range of immunotherapies, and this cannot be only immune checkpoint inhibitors, but can be CAR T-cells, oncolytic viruses, also targeted therapy, will likely be a dominant theme in the coming years. This combination will be based on the specific molecular and immuno feature of the cancer of the patient.  Then we need an enhanced delivery system. This is really important because you know now we have a next generation antibody. An example are the bicyclic. So you use FC fragment that are very short, with a low molecular weight, and this short fragment can be bispecific, so can target at the same time a target antigen and improving the immune system. And so the development of this novel delivery system, including also nanoparticles or engineered viral vectors, can enhance the penetration in the tumor bed and the bioavailability of bispecific antibodies. Importantly, we need to reduce toxicity. Until now, bispecifics are very toxic. So the more we are efficient in delivering in the tumor bed, the more we will reduce the risk of toxicity. So it will be mandatory to reduce off-target effects and to minimize toxicity.  And finally, the expansion in new indication. So I really believe you raised an excellent point. We need to design studies in the neoadjuvant setting in order to better understand with multiple biopsies which is the effect on the tumor microenvironment and the tumor itself, and to generate hypotheses for potential trials or in the neoadjuvant setting or in those patients with residual disease.  So, in my opinion, as we refine design, optimize patient selection, and explore new combination, in the future we will have more opportunity to integrate bispecifics in the standard of care. Dr. Hope Rugo: I think it is particularly helpful to hear what we are going to be looking for as we move forward to try and improve efficacy and reduce toxicity. And the ability to engineer these new antibodies and to more specifically target the right proteins and immune effectors is going to be critical, of course, moving forward, as well as individualizing therapy based on a specific tumor biology.  Hearing your insights has been great, and it really has opened up a whole area of insight into the field of bispecifics, together with your excellent contribution to the ASCO Educational Book. Thank you so much for sharing your thoughts and background, as well as what we might see in the future on this podcast today. Dr. Giuseppe Curigliano: Thank you very much for the invitation and for this excellent interview. Dr. Hope Rugo: And thanks to our listeners for joining us today. You will find a link to the Ed Book article we discussed today in the transcript of this episode. It is also, of course, on the ASCO website, as well as on PubMed. Please join us again next month on By the Book for more insightful views on the key issues and innovations that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Giuseppe Curigliano @curijoey Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  Dr. Giuseppe Curigliano: Leadership: European Society for Medical Oncology, European Society of Breast Cancer Specialists, ESMO Open, European Society for Medical Oncology Honoraria: Ellipses Pharma Consulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol-Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boerigher, GSK, Seattle Genetics, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines, Gilead Sciences Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, Exact Sciences Research Funding: Merck Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi Sankyo, AstraZeneca      

Bill George is a celebrated leader who served as Chair and CEO of Medtronic, the world's leading medical technology company. He is an executive fellow at Harvard Business School, where he has taught leadership since 2004, and is the bestselling author of many books, including Discover Your True North. Bill also served as a director at Goldman Sachs, ExxonMobil, Novartis, Target, the Mayo Clinic, and World Economic Forum USA. In this episode of ⁠the Elevate Podcast⁠, Bill joins host Robert Glazer to discuss his leadership career, the importance of purpose-driven leadership, and more. To learn more about core values, check out The Compass Within. Thank you to the sponsors of The Elevate Podcast Mizzen & Main: ⁠⁠mizzenandmain.com⁠⁠ (Promo Code: elevate20) Shopify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Indeed: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠indeed.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Masterclass: ⁠⁠masterclass.com/elevate⁠⁠ Found: ⁠⁠found.com/elevate Learn more about your ad choices. Visit megaphone.fm/adchoices

For decades, allergists have focused on blocking what happens outside the mast cell: histamine, IgE, and interleukins. But now, there's a new way to stop allergic inflammation before it even starts: by targeting what happens inside the cell with BTK Inhibitors. Dr. Payel Gupta and Kortney are joined by Dr. Matthew Giannetti to unpack what BTK actually does and why inhibiting it represents an exciting breakthrough in allergy and immunology. Together, they explore how BTK inhibitors work, why this inside-the-cell approach is different from anything before, and what it could mean for people living with chronic spontaneous urticaria (CSU). What the episode covers about BTK inhibitors: BTK explained: Bruton's tyrosine kinase is a pivotal “last step” before mast-cell degranulation. How BTK inhibitors work: Blocking BTK can stop histamine release downstream of many outside triggers. The science: Why BTK binding is irreversible for each molecule and how the body “re-makes” BTK over time. Safety in brief: A look at petechiae (small pinpoint spots), what to monitor, and how shared decision-making guides treatment choices. The future of BTK inhibitors: Exploring their potential role in other allergic conditions.    ____ Made in partnership with The Allergy & Asthma Network. Thanks to Novartis for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Episode Description:  Listen as Kim Beer, Senior Vice President of Policy and External Affairs with the National Health Council, and Dermatologist, Dr. Jeffrey Cohen discuss the 2025 Medicare changes in relation to psoriatic disease and what's to come in 2026 with Jason Harris, Vice President of Government Relations and Advocacy at NPF.  Join this discussion about what changes occurred with Medicare in 2025 that impact psoriatic disease care, outcomes to date, what's to come in 2026, and what you should consider when choosing health care plans during open enrollment with Kim Beer, Senior Vice President of Policy and External Affairs with the National Health Council, Dermatologist, Dr. Jeffrey Cohen, Director of the Psoriasis Treatment Program at Yale University School of Medicine, and Jason Harris, Vice President of Government Relations and Advocacy at NPF.  The intent of this episode is to increase knowledge of the 2025 Medicare changes, what's to come, and how such changes impact psoriatic disease from coverage of prescriptions to overall health care. This episode is sponsored by Novartis. Timestamps:   (0:24) Intro to Psoriasis Uncovered and guest welcome Kim Beer, Senior Vice President of Policy   and External Affairs with the National Health Council, and Dermatologist, Dr. Jeffrey Cohen, Director of the Psoriasis Treatment Program at Yale School of Medicine. (2:25) Perspectives on current health care coverage in Medicare.    (5:14) Biggest changes to Medicare in 2025. (6:36) What is the Medicare Prescription Payment Plan and price negotiation for specific medications. (8:22) Challenges associated with the 2025 Medicare changes from a physician's perspective. (13:10) Price negotiation process via CMS  (Centers for Medicare and Medicaid Services) with the first 10 drugs price effective in 2026.   (17:52) Plan ahead and what to anticipate when choosing the right Medicare plan. (20:04) What the National Health Council and other patient advocacy organizations are doing to assess the impact of the CMS changes and identify steps for moving forward. (21:49) Medicare changes for 2026 that affect deductibles for health care services, prescription drug coverage, and vaccinations. (28:38) Potential assistance options for people who have Medicare insurance. (31:32) The role of patients in providing feedback on policy changes. (33:45) Changing from a commercial insurance plan to a Medicare Plan and what to think about when viewing plan options during the open enrollment period. (37:07) Be part of the process – let your voice be heard by sharing your experiences to help effect change. 3 Key Takeaways: ·       There are four key parts to Medicare health insurance (Part A, B, C and D) which underwent changes in 2025 including a payment cap for prescriptions and availability of a 12 month Prescription Payment Plan to opt in for medications. Additional changes are coming in 2026 including enactment of a price negotiated list of 10 medications. ·       The impact of such changes are both positive (better predictability and affordability) yet also reactionary. Such changes and potential impact should be considered when identifying plan coverage for health care and prescriptions during the open enrollment Medicare period of October 15 to December 7th.   ·       Be involved by telling your story about the impact of Medicare changes and find a trusted health care provider who is willing to work with you to identify an effective treatment plan that aligns with your health care needs and coverage. Guest Bios:   Dermatologist Jeffrey Cohen, M.D., MPH, is the Director of the Psoriasis Treatment Program and the Director of Safety with the Department of Dermatology at Yale University School of Medicine where he is also an Associate Professor of Dermatology and Biomedical Informatics and Data Science. Dr. Cohen treats a variety of skin conditions with a special interest in diseases of the immune system such as psoriasis and eczema tailoring treatments for each individual. He is the author of over 150 peer-reviewed articles on psoriasis and other topics in dermatology. Dr. Cohen serves on the Editorial Board of the Journal of the American Academy of Dermatology, is a Senior Editor for NPF's professional journal for health care providers Journal of Psoriasis and Psoriatic Arthritis, is a Councilor of the International Psoriasis Council, and serves on the Medical Board of the National Psoriasis Foundation.  Kimberly (Kim) Beer is Senior Vice President of Policy and External Affairs at the National Health Council (NHC) of which the National Psoriasis Foundation is a member. Kim leads strategic policy initiative and advocacy efforts to improve the lives of individuals with chronic conditions and disabilities. As a member of the NHC's executive leadership team, she helps to ensure access to high-quality, affordable healthcare for all Americans which includes advocating for policy and health care benefits within Medicare. Resources: For more reources and information about Medicare Contact the Patient Navigation Center to learn more about Medicare, find a health care provider, learn about treatments, or programs that may lower costs.